On January 18, 2019, iKang Healthcare Group, a major provider in China's fast-growing private preventive healthcare services market, announced that it has completed its merger with IK Healthcare Merger Limited, a special-purpose vehicle controlled by a buyer group consisting of certain founders and executive officers of iKang and affiliates of or funds managed or advised by Yunfeng Capital, Alibaba Group, and Boyu Capital. As a result of the merger, the buyer group acquired iKang in a cash transaction valued at approximately $1.5 billion. Wilson Sonsini Goodrich & Rosati acted as U.S. legal counsel to the sponsors and as lead counsel to the buyer group in the transaction.

The Wilson Sonsini team that advised the sponsors and buyer group in the transaction included partners Weiheng Chen and Jie Zhu and attorneys Jing Xu and Jill Sheng.

For more information, please see iKang's press release.